Original-Research: Pentixapharm Holding AG (von NuWays AG): BUY
^ Original-Research: Pentixapharm Holding AG - from NuWays AG 31.07.2026 / 09:00 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.
How this was made
The 30-second read
Why it matters
Secured net proceeds and extended cash runway into early 2028 reduce financing overhang and frame two upcoming decision points: first patient in (H2 2026) and potential commercial partnering (likely in 2027, signing window H1 2027).
Market read
Traders may adjust expectations for funding risk and the probability-weighted path to Phase 3 milestones and partnering discussions.
What to watch
Rights-issue execution reduces near-term funding risk, but dilution and the invasive reference standard dependency could still affect recruitment speed and eventual data quality.
Background
NuWays AG issues an update recommendation (BUY) for Pentixapharm Holding AG, focusing on financing secured via a rights issue and the planned Phase 3 PANDA study for PentixaFor.
Ticker impact
Pentixapharm Holding AG is the subject of a NuWays research update, citing a rights issue and Phase 3 catalyst timing for PentixaFor.
Near-term sentiment may improve on the capital runway extension and clearer clinical timeline, but the piece is still an analyst update rather than a new clinical readout.
The text discloses net proceeds, pro forma cash, and specific study/partnering timing, which can move expectations. However, it is not a primary company filing or trial result, limiting certainty on realized price impact.
Market effects
Supports the radiopharma/diagnostic PET/CT narrative by emphasizing a scalable installed base and a non-oncology patient pool.
Primarily impacts German-listed small/mid-cap biotech sentiment rather than broad European sector flows.
Moderate, as it references global radiopharma demand drivers (e.g., PSMA PET infrastructure) but does not introduce a new global policy or market-wide datapoint.
Counterpoint
A BUY note can overstate certainty around enrollment pace and partnering timelines; without trial execution updates, the catalysts remain expectations.
Key entities
- issuerPentixapharm Holding AG
Company conducting Phase 3 PANDA for diagnostic agent PentixaFor, with financing secured via a rights issue.
- product_candidatePentixaFor
Lead diagnostic agent intended to replace adrenal vein sampling with a PET/CT scan.
- clinical_programPANDA
Phase 3 study for PentixaFor, with first patient in targeted for H2 2026.
- shareholderEckert Wagniskapital
Anchor shareholder that exercised rights in full in the capital increase.
